Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

Myriad Genetics (MYGN) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY25 Guidance

August 5, 2025 4:36 PM EDT

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.05, $0.06 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $213.1 million versus the consensus estimate of $201.91 million.

GUIDANCE:

Myriad Genetics sees FY2025 EPS of ($0.02)-$0.02, versus the consensus of... More